Search results for "Mab" in Articles / App Notes
Article
Process Development: 2020 Reflections and 2021 Possibilities
…ctive production of therapeutics is process chromatography, particularly for monoclonal antibodies (mAb) and gene therapies. This makes knowing the current status of process chromatography and what t…
Article
Reimagining Affordable Biosimilars
Advances in preclinical development
Analytics
The complexity of biotherapeutic molecules, in particular monoclonal antibodies (mAbs), lends themselves to fascinating targets for analytical…
Article
Flexible Facilities for Viral Vector Manufacturing
While the initial project looked at a monoclonal antibody (mAb) facility, the team plans to extend the concept to cell and gene therapy production.
Cytiva has amassed expertise in modular design a…
Article
Best Practices for Selecting a Top-Quality Cell Line
Before scaling up to bioreactors, the productivity level for monoclonal antibodies (mAbs) should be 2–7 g/L (fed-batch culture in shake flask) or greater, observes Selexis CEO Igor Fisch. Once scaled …
Article
Biopharmaceutical Process Development: 2018 Lessons and 2019 Predictions
Numerous readers also explored semi-continuous processing, specifically an application note about how various unit operations in a laboratory-scale monoclonal antibody (mAb) process can be connected a…
Article
Unifying Continuous Biomanufacturing Operations
included the upstream and preliminary downstream steps of a monoclonal antibody (mAb) in 28 days, with the secondary downstream steps taking an additional two-and-a-half days (3).
A 1998 analysis …
Article
Improvements in Protein A Chromatography
The Protein A step is platformable so that the same buffers and conditions can be used for many different clinical antibody candidates. This allows for fast step development. Alternative technologies …
Article
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
Reichert, MAbs. 7 (1), pp. 1–8 (2015).
2. S.D. Wijesuriya, R.L. Cotter, and A.H. Horwitz, Protein Expr. Purif. 92 (1), pp. 14–20 (2013).
3. D. Guo et al., Biotechnol. Bioeng. 107 (1), pp. 163–17…
Article
Biopharma in 2015: A Year for Approvals and Innovations
Immediately following its acquisition by Pfizer, Hospira announced a major milestone in February, 2015: its first monoclonal antibody (mAb) biosimilar was approved for use in West Europe.2 And in Nove…
Article
Modular Manufacturing Platforms for Biologics
By using modularization and the other aforementioned technologies such as continuous manufacturing, facilities to produce monoclonal antibodies (mAbs) can also be operational 12 months after project i…